Immunology and immunotherapy of melanoma

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Clinical toxicity of interferons in cancer patients: a review.

1986 • 601 citations

Biologic Therapy of Cancer

1992 • 476 citations

Interleukin-2 toxicity.

1991 • 450 citations

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 • 432 citations

Inhibition of murine natural killer cell activity by prostaglandins.

1980 • 418 citations

CARCINOID SYNDROME

1961 • 405 citations

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

1987 • 404 citations

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

1992 • 394 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

1989 • 349 citations

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

1989 • 337 citations

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

1989 • 332 citations

Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

1988 • 324 citations

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1990 • 300 citations

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

1990 • 296 citations

Vitiligo in patients with metastatic melanoma: A good prognostic sign

1983 • 292 citations

Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.

1986 • 259 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

1989 • 240 citations

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.

1987 • 212 citations

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

1990 • 206 citations

Active-specific immunotherapy for melanoma.

1990 • 186 citations

In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma

1989 • 184 citations

Comparison of Intramuscular and Intravenous Recombinant Alpha-2 Interferon in Melanoma and Other Cancers

1985 • 173 citations

A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate

1983 • 171 citations

The Murine Antitumor Immune Response and Its Therapeutic Manipulation

1984 • 164 citations

Safety and tolerance of recombinant interferon alfa-2a (roferon®-A) in Cancer Patients

1986 • 159 citations

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

1988 • 153 citations

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.

1989 • 134 citations

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

1990 • 133 citations

Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating Lymphocytes

1988 • 128 citations

Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.

1984 • 124 citations

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.

1991 • 120 citations

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1991 • 119 citations

Interleukin-2 in cancer therapy.

1988 • 115 citations

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

1991 • 99 citations

Low doses of interferon alpha result in more effective clinical natural killer cell activation.

1985 • 87 citations

Effects of anticancer drugs on the immune system in humans.

1989 • 86 citations

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

1990 • 84 citations

Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience.

1985 • 82 citations

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

1990 • 82 citations

Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II).

1980 • 79 citations

Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

1989 • 77 citations

Studies of interferons in the therapy of melanoma.

1991 • 67 citations

Viral oncolysate in the management of malignant melanoma. II. Clinical studies

1977 • 63 citations

Adriamycin-induced modulation of host defenses in tumor-bearing mice.

1992 • 63 citations

Effective chemotherapy for melanoma after treatment with interleukin-2

1992 • 57 citations

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

1989 • 56 citations

Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro.

1986 • 55 citations

Viral oncolysate in the management of malignant melanoma.II. Clinical studies

1977 • 54 citations

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

1989 • 54 citations

Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

1984 • 53 citations

A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.

1987 • 52 citations

Systemic chemotherapy for metastatic melanoma.

1988 • 50 citations

Monoclonal Antibody Imaging of Human Melanoma

1986 • 48 citations

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

1991 • 48 citations

Human tumor antigens and specific tumor therapy

1988 • 47 citations

Preparation and characterization of a polyvalent human melanoma antigen vaccine.

1986 • 47 citations

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

1989 • 45 citations

Indomethacin enhancement of immunocompetence in melanoma patients.

1981 • 45 citations

Disseminated Malignant Melanoma and Recombinant Interferon: Analysis of Seven Consecutive Phase II Investigations

1990 • 44 citations

Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

1986 • 43 citations

Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients

1988 • 43 citations

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.

1992 • 42 citations

Sequential chemoimmunotherapy for metastatic melanoma.

1991 • 42 citations

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

1990 • 42 citations

Viral oncolysates in patients with advanced ovarian cancer

1988 • 39 citations

A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma

1977 • 37 citations

Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma

1992 • 36 citations

Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment.

1981 • 35 citations

Regulation of cell growth by interferon

1987 • 35 citations

Multiple tumoricidal effector mechanisms induced by adriamycin.

1984 • 34 citations

Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2.

1992 • 34 citations

Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial.

1992 • 34 citations

Augmented Tumor-Associated Antigen Expression by Interferons1

1988 • 33 citations

the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2

1990 • 31 citations

Phase II Trial of Recombinant Tumor Necrosis Factor in Disseminated Malignant Melanoma

1992 • 29 citations

Phase II Study of Recombinant α-Interferon in Malignant Melanoma

1990 • 27 citations

Serological and Biochemical Analyses of Monoclonal Antibodies to Human Melanoma-Associated Antigens

1982 • 27 citations

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

1990 • 25 citations

Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia.

1987 • 25 citations

Sequential Dacarbazine/Cisplatin and Interleukin-2 in Metastatic Melanoma

1991 • 24 citations

Immunotherapy with monoclonal antibodies in metastatic melanoma

1992 • 23 citations

Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.

1991 • 22 citations

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

1990 • 20 citations

Biological approaches to cancer treatment: Biomodulation

1993 • 18 citations

Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma

1989 • 18 citations

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

1989 • 18 citations

Phase II Trial of Cimetidine in Metastatic Melanoma

1991 • 17 citations

Principles of combining biomodulators with cytotoxic agents in vivo.

1992 • 17 citations

Melanoma tumor vaccine: Five‐year follow‐up

1991 • 16 citations

Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.

1991 • 15 citations

A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors

1991 • 15 citations

Custom-tailored drug immunoconjugates in cancer therapy.

1991 • 15 citations

Histamine type 2-receptor antagonists and cancer immunotherapy.

1990 • 13 citations

A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.

1988 • 12 citations

Augmented immunity in cancer patients treated with alpha-interferon.

1985 • 12 citations

IL-2: a review of current knowledge

1989 • 10 citations

Vaccines 88: New Chemical and Genetic Approaches to Vaccination (Prevention of AIDS and other viral, bacterial and parasitic diseases)

1989 • 9 citations

Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center

1989 • 9 citations

Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer

1992 • 9 citations

Immunological approaches to cancer treatment

1980 • 9 citations

The effect of cimetidine treatment on suppressor T cells in duodenal ulcer patients

1984 • 8 citations

Up-regulation of IL-2 induced lymphokine activated killer cell activity by cisplatin and FK-565: involvement of calcium ion

1992 • 7 citations

CONTINUOUS ORAL INDOMETHACIN (INDO) AND RANITIDINE (RANT) AND CONTINUOUS VENOUS INFUSION INTERLEUKIN-2 (IL-2) IN ADVANCED RENAL CARCINOMA

1992 • 7 citations

Lymphokine-activated killer cells/tumor-infiltrating lymphocytes therapy: efficacy, toxicity, controversies.

1990 • 4 citations

Effect of a Single Injection of Cyclophosphamide on Immunization Therapy of Metastases Remaining after Excision of Dermal Primary Tumors in Guinea Pigs

1984 • 4 citations

Interleukin-2 and immunoglobulin increases with H2-antagonists in humans.

1989 • 4 citations

A PHASE IB TRIAL OF MURINE MONOCLONAL ANTIBODY R24 (ANTI-GD3) IN METASTATIC MELANOMA

1992 • 3 citations

SUBJECT INDEX

1987 • 1 citations

Deleted Work

1955 • 0 citations